Atlas Trials

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Clinical trial NCT05593328 · COMPLETED

Trial details

NCT number
NCT05593328
Sponsor
Cardiff Oncology
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Colorectal CancerMetastatic Colorectal Cancer
Start date
2023-03-17
Primary completion
2024-12-09
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.